Evidence map›Paper›PMID 22736791›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2012

Estrogen metabolism and mammographic density in postmenopausal women: a cross-sectional study.

Barbara J Fuhrman, Louise A Brinton, Ruth M Pfeiffer, Xia Xu, Timothy D Veenstra, Barbara E Teter, Celia Byrne, Cher M Dallal, Maddalena Barba, Paola C Muti and 1 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Barbara J FuhrmanHormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA. fuhrmanb@mail.nih.gov
Louise A Brinton
Ruth M Pfeiffer
Xia Xu
Timothy D Veenstra
Barbara E Teter
Celia Byrne
Cher M Dallal
Maddalena Barba
Paola C Muti
Gretchen L Gierach
National Cancer Institute · USMcMaster University · CAUniversity at Buffalo, State University of New York · USJuravinski Cancer Centre · CAUniformed Services University of the Health Sciences · US

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA CP010126NCI NIH HHS HHSN261200800001ENCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

backgroundProspective studies have consistently found that postmenopausal breast cancer risk increases with circulating estrogens; however, findings from studies of estrogens and mammographic density (MD), an intermediate marker of breast cancer risk, have been inconsistent. We investigated the cross-sectional associations of urinary estrogens, and their 2-, 4-, and 16-hydroxylated metabolites with MD.

methodsPostmenopausal women without breast cancer (n = 194), ages 48 to 82 years, and reporting no current menopausal hormone therapy use were enrolled at a clinic in Western NY in 2005. Urinary estrogens and estrogen metabolites were measured using mass spectrometry. Percent MD and dense area (cm(2)) were measured using computer-assisted analyses of digitized films. Linear regression models were used to estimate associations of log-transformed estrogen measures with MD while adjusting for age, body mass index (BMI), parity, and past hormone therapy use.

resultsUrinary concentrations of most individual estrogens and metabolites were not associated with MD; however, across the interdecile range of the ratio of parent estrogens (estrone and estradiol) to their metabolites, MD increased by 6.8 percentage points (P = 0.02) and dense area increased by 10.3 cm(2) (P = 0.03). Across the interdecile ranges of the ratios of 2-, 4-, and 16-hydroxylation pathways to the parent estrogens, MD declined by 6.2 (P = 0.03), 6.4 (P = 0.04), and 5.7 (P = 0.05) percentage points, respectively. All associations remained apparent in models without adjustment for BMI.

conclusionIn this study of postmenopausal women, less extensive hydroxylation of parent estrogens was associated with higher MD. IMPACT: Hydroxylation of estrogens may modulate postmenopausal breast cancer risk through a pathway involving MD.

Indexed as

MammographyAgedAged, 80 and overBody Mass IndexCross-Sectional StudiesEstrogensFemaleHumansHydroxylationLinear ModelsMiddle AgedPostmenopauseEstrogens

Identifiers

PMID22736791
PMCPMC3436977
OpenAlexW2134111015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.